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Objective: The objective of this paper is to assess the reliability and validity of the Spanish 
translation of the Clinical Outcomes in Routine Evaluation – Outcome Measure, a 34-item self-
report questionnaire that measures the client’s status in the domains of Subjective well-being, 
Problems/Symptoms, Life functioning, and Risk.
Method: Six hundred and forty-four adult participants were included in two samples: the clinical 
sample (n192) from different mental health and primary care centers; and the nonclinical 
sample (n452), which included a student and a community sample.
Results: The questionnaire showed good acceptability and internal consistency, appropriate 
test–retest reliability, and acceptable convergent validity. Strong differentiation between clinical 
and nonclinical samples was found. As expected, the Risk domain had different characteristics 
than other domains, but all findings were comparable with the UK referential data. Cutoff scores 
were calculated for clinical significant change assessment.
Conclusion: The Spanish version of the Clinical Outcomes in Routine Evaluation – Outcome 
Measure showed acceptable psychometric properties, providing support for using the question-
naire for monitoring the progress of Spanish-speaking psychotherapy clients.
Keywords: CORE-OM, outcome measure, reliability, validity, psychometric validation
Introduction
This paper reports the psychometric properties of the Spanish version of Clinical 
Outcomes in Routine Evaluation – Outcome Measure (CORE-OM). The 
CORE-OM was designed mainly for practice-based evidence (a complement to 
evidence-based practice).1 We expected that the Spanish translation of the CORE-OM 
would be a useful, reliable, and valid instrument suitable to be widely used for research 
and practice in Spain and in some countries in which Spanish is spoken in similar 
form to that used in Spain. The translation should also prove a useful base, with 
the original English version, for countries where local Spanish usage is sufficiently 
different from that in Spain that a somewhat different translation will be needed.
From its origin, the measure was designed to be pan-theoretical (not associated with 
a school of therapy) and pan-diagnostic (not focused on a single presenting problem), 
and was driven by what practitioners and clients considered to be the most important 
generic aspects of psychological well-being, and change in therapies, to be measured. 
It is recommended to be used before and at the end of therapy.
The CORE-OM measure is copyleft; that is, it can be reproduced without payment 
of any license fee if it is not changed in any way.2 Translations were done following the 
Correspondence: Guillem Feixas
Department of Personality, Assessment 
and Psychological Treatments, 
Faculty of Psychology, University of 
Barcelona, Passeig Vall dHebron, 171, 
08035 Barcelona, Spain
Tel 34 93 312 5100
Email gfeixas@ub.edu 
Neuropsychiatric Disease and Treatment 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1458
Trujillo et al
CORE System Trust (CST) protocol, and with the supervision 
and guidance of Chris Evans (CE). Copyright violations are 
illegal, but CST and CE welcome collaboration on new trans-
lations to the protocol. All CORE instruments are available 
to download from,3 which provides more information about 
the system, instruments, and translation protocol. Information 
focused on the CORE-OM in Spanish is at.4
There are many fields in which CORE-OM has dem-
onstrated its utility having been used in areas as varied as 
benchmark studies,5,6 assessment of outcome of psycho-
logical therapies in primary and secondary settings,7–10 
studies of treatment processes,11–13 assessment of the 
psychological well-being of individuals in nonclinical 
occupational settings,14 and examination of psychologi-
cal health among university students who were receiving 
university counseling.15,16 Acceptability and psychometric 
properties have been demonstrated with diverse samples, 
for example, older people and patients with eating 
disorders.17,18 Though designed more for practice-based 
evidence, the CORE-OM has been used in randomized 
controlled trials.19–21
CORE-OM has been translated, following a clear and 
thorough protocol,22 into over 20 languages, with that number 
growing. Evaluation of the psychometric properties of the 
translated measure has been completed showing comparable 
psychometric properties to that found for the English ver-
sion in the UK for a growing number of languages including 
Italian,23 Portuguese,24 Swedish,25 Lithuanian,26 Icelandic,27 
and Croatian,28 and many others are nearing completion 
including a Catalan version. All forms are widely used 
as a routine change measure in a range of health care set-
tings in the UK and increasingly in other languages and 
countries.13,29–32
This study was designed to assess the psychometric 
properties of the Spanish translation of the CORE-OM, 
and hence its suitability to be used in routine assessment 
of mental health interventions in Spain and perhaps other 
Spanish-speaking countries.
Method
The Spanish version
For the translation and adaptation of the CORE-OM to 
Spanish, we followed the steps established by interna-
tional groups and the CST protocol including participation 
of a member of the group who designed the instrument 
(CE).33 This process is congruent to the guidelines of the 
International Test Commission,34 and it emphasizes the 
importance of translating the items according to their con-
textualized meaning in culture and the environment in which 
they will be applied, as well as making them understandable 
for the most varied range of possible potential users. It does 
not rely excessively on back-translation in order to avoid too 
literal translations. To seek for improvement of the resulting 
version, we requested the collaboration of 12 people from 
different parts of Spain, selected because of their high level 
of English proficiency. Ten of them responded to the request 
by providing a translation. Six of them were professionals in 
psychology, and four were lay people. With this material, a 
working session was organized with the participation of two 
of the professionals of psychology and two of the lay people 
who collaborated with the translation, along with a member 
of the CST (CE) who acted as a consultant or supervisor. In 
this session, each item was discussed taking into account 
the available translations. For each item, the best option was 
chosen by consensus. A first draft came out of this process 
which was reviewed by three experts in psychology with 
over 20 years of experience in clinical settings who made 
some modifications that were discussed by email with CE. 
This revised version was submitted to extensive scrutiny by 
a group of 64 people (between 16 and 76 years, all of them 
from different conditions and linguistic backgrounds, and 
fully proficient in Spanish, 12 of them were professionals 
of psychology, and 52 lay people) who were asked to read 
it carefully and to judge whether the items were understand-
able and clear. They were also encouraged to make all the 
comments they deemed appropriate with regard to the way 
items were written.
Afterward, the comments and observations made were 
discussed by the three experts mentioned, and issues that 
seemed to need discussion of the original English were shared 
with CE, until a final version was achieved. This version 
was delivered to an experienced, bilingual English–Spanish 
translator, with a degree in psychology and without access 
to the original version, to back-translate. Looking at this 
back-translation, neither the experts nor the member of the 
CST considered necessary to make any modification of the 
latest version, at which point it became the CST-approved 
translation into Spanish.
From that version,33 the shorter versions (designed for 
routine use in therapy sessions, for screening and ongo-
ing monitoring: CORE-SFA, CORE-SFB, CORE-10, and 
CORE-5, all in male and female versions35) were typeset and 
made available through webpages, initially4 and now also.22
Participants and procedures
The study protocol was approved by the Bioethics Commit-
tee of the University of Barcelona (ref. IRB0003099) and by 
the ethical committees of the centers taking part in the study. 
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All the participants were informed of the implications of 
the study and signed an informed consent document before 
enrolling. The study included 644 adult participants in two 
samples (Table 1). The clinical sample (n192) comprised 
patients from nine mental health centers and from some 
primary care centers in the Barcelona area. The CORE-OM 
was included in the routine pretreatment assessment of these 
centers, and it is this routine clinical data that are reported on 
in this paper. All patients who were referred for psychological 
treatment between March 2012 and May 2013 in the centers 
collaborating in the study were included in the study. Profes-
sionals were asked to exclude from these referrals inpatients 
and outpatients with severe psychological disorders. Another 
exclusion criterion was insufficient linguistic competence to 
communicate in Spanish.
The nonclinical sample (n452) included a student and a 
community nonstudent sample, between 18 and 70 years of 
age (inclusion criteria) who were assessed in the same period 
from March 2012 to May 2013 and had sufficient linguistic 
competence to communicate in Spanish. The latter (n127) 
consisted of volunteers and/or their relatives who were not 
receiving psychological treatment (exclusion criterion). 
The student sample (n325) was drafted from the Faculty 
of Psychology of the University of Barcelona; 219 were 
undergraduate students from four different subject areas, 
and 106 were master-level students.
Forty-six participants of the community sample and 32 of 
the student sample agreed to take part in the test–retest survey 
completing the questionnaire twice; this second administra-
tion of the questionnaire took place between 15 and 30 days 
after the first one. For student, test and retest were made in 
their classrooms with a 2-week test–retest interval; for the 
community sample, all the participants who completed the 
first assessment were contacted by phone ^ 2 weeks later and 
were invited to participate in the retest survey. For those who 
accepted, the questionnaire was sent in an envelope, and 
they completed and returned it. Test–retest stability was not 
measured in the clinical sample as that would have involved 
significant interference with normal clinical management 
of these participants. This was in line with the UK original 
study where there was no test–retest stability examination 
in the clinical sample for the same reason.36
Instruments and measures
CORE-OM is a 34-item self-report questionnaire that 
assesses the client’s status in the domains of Subjective 
well-being (four items), Problems/Symptoms (12 items), 
Functioning (12 items), and Risk (six items).36,37 Eight of 
the items are positively cued (items 3, 4, 7, 12, 19, 21, 31, 
and 32). The focus is on the last 7 days, and items are scored 
in a five-point scale ranging from 0 (not at all) to 4 (most or 
all the time), where higher scores on all domains indicate 
more problems and high levels of psychological distress 
even for the Subjective well-being scale. The domains were 
named to designate their item content but never envisaged 
to be psychometric factors.35,38 The Subjective well-being 
domain comprises four items capturing this aspect. The 
Problems/Symptom domain includes four items address-
ing anxiety, four for depression, and two each for physical 
problems and trauma. The Functioning domain includes four 
items covering general/work functioning, four addressing 
close relationships, and four for social functioning. The 
Risk domain has four items about risk to self and two about 
risk to others.
The CORE-OM was designed to be user-friendly for 
both clients and practitioners.35,39 It takes 5–10 minutes to 
complete, and the total and domain scores are reported as 
means across items. Prorating, that is, using the item mean 
even with missing items, is recommended as long as 10% 
of the items in the score are missing.36
Psychometric properties were excellent in the original 
UK testing and in all subsequent explorations showing high 
internal consistency (Cronbach ] between 0.75 and 0.94 
for all scores, the lowest for Risk) and test–retest stability 
Table 1 Demographic data
Sample Total  
(missing data for sex)
Females (%) Males (%) Mean  
age (SD)
Age range 
(years)
Nonclinical sample 452 (15) 343 (75.9) 94 (20.8) 29.3 (14.4) 1876
Students 310 (15) 250 (76.9) 60 (18.5) 23.2 (6.1) 1869
Community sample 127 (0) 93 (73.2) 34 (26.8) 44.4 (17.6) 2076
Clinical sample (outpatients) 192 (1) 130 (67.7) 61 (31.8) 41.3 (14.9) 1878
Primary care 44 (0) 29 (65.9) 15 (34.1) 41.8 (12.7) 2276
Secondary care 147 (1) 101 (68.2) 46 (31.1) 41.1 (15.5) 1878
Testretest sample 78 (0) 54 (69.2) 24 (30.8) 34.9 (18.8) 1869
Students 32 (0) 26 (81.3) 6 (18.8) 20.7 (3.8) 1834
Community sample 46 (0) 28 (60.9) 18 (39.1) 44.8 (18.8) 2069
Abbreviation: SD, standard deviation.
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of 0.91 (Spearman’s l 0.91 for 1-week test–retest in a 
student sample). Discriminant validity showed large differ-
ences between clinical and nonclinical samples (Cohen’s d 
from 0.71 Risk to 1.77 Problems/Symptoms) and high cor-
relations with measures which are conceptually close, for 
example, Beck Depression Inventory-II (BDI-II) (l0.85) 
and Symptom Checklist 90 Revised (SCL-90-R) (l0.88). 
The CORE-OM is also sensitive to change in therapies.15,36 
As expected, the domains did not show neat factorial separa-
tion, but an oblique structure in which Risk items are clearly 
separated from other items and two strongly correlated main 
problem dimensions of the positively and the negatively cued 
items gave a moderate and just acceptable fit on confirmatory 
factor analysis.38
BDI-II is a 21-item self-administered inventory designed 
to measure the intensity of depressive symptoms in psy-
chiatric and nonpsychiatric populations of both adults and 
adolescents.40 Items are rated on a four-point scale (0–3), 
and total scores are obtained by tallying the ratings for all 
21 items. Scores range from 0 to 63, with higher scores 
reflecting increased depressive severity. The BDI-II 
requires ^ 5–10 minutes to complete and may be administered 
to individuals 13–80 years of age. We used the Spanish-
language version of the BDI-II.41
SCL-90-R is a 90-item self-report symptom inven-
tory designed to screen for a broad range of psychological 
problems.42 Each of the 90 items is rated on a five-point 
Likert scale of distress, ranging from “not at all” (0) to 
“extremely” (4). Subsequently, the answers are combined in 
nine primary symptom dimensions: Somatization, Obsessive-
Compulsive, Interpersonal Sensitivity, Hostility, Depression, 
Anxiety, Paranoid Ideation, Phobic Anxiety, and Psychoti-
cism. In addition, three global indices provide measures of 
overall psychological distress: the Global Severity Index, 
the Positive Symptom Total, and the Positive Symptom 
Distress Index. We used the Spanish-language version of 
the SCL-90-R.43
Analyses
To facilitate a comparison with the UK data, we followed 
the original study by assessing acceptability, internal con-
sistency, test–retest reliability (with 15- to 30-day interval), 
influence of age and sex, correlations between domain 
scores, and discriminant validity against sample, reflected 
in the differences between clinical and nonclinical sample, 
along with the calculation of cutoff scores, and convergent 
validity in terms of the correlations between CORE-OM’s 
scores and those on the BDI-II and SCL-90-R.36 Following 
the UK study, most analyses were reported for each of the 
four content domains (Subjective well-being, Problems/
Symptoms, Life/social functioning, and Risk) as well as 
for total scale, and for score of all items except those in 
the Risk domain. Internal reliability was reported as Cron-
bach’s ] for the subsample with no missing item data,44 
but results for domain scores were reported where a score 
could be computed by prorating up to 10% of missing 
items. To test the equality for the different coefficients in 
the samples and subsamples, a Felt’s procedure was done.45 
Again following the UK validation study, nonparametric 
correlation coefficients (Spearman’s l) and nonparamet-
ric tests of differences in central location of distributions 
(Wilcoxon test) were used as scores did not conform to 
Gaussian distributions. The BDI-II40,41 and the SCL-90-R42,43 
were used to test convergent validity with other self-report 
measures. Clinically significant change was calculated 
according to the c criterion that uses a cutoff point based 
on the contrast between dysfunctional and general popu-
lation samples.46 Analyses were conducted using SPSS, 
version 20.0. As in the original paper, the methodology 
was mainly exploratory and descriptive rather than one of 
null hypothesis testing; wherever possible, 95% confidence 
intervals (CIs) were reported rather than P-values. This gave 
a test approximating to testing for P0.05. Comparisons of 
parameters within this sample and against those reported in 
the UK data were generally informed in terms of overlap 
or not of CIs.15
This paper did not follow the original UK analysis in 
including a principal component analysis, as subsequent 
UK papers have shown that the CORE-OM, as its authors 
expected, has a complicated factor structure that would need 
larger clinical and nonclinical samples for the Spanish data 
than we have to date.6 More psychometric exploration will 
be reported later when such significantly larger samples are 
available.
Results
Acceptability
All of the questionnaires have sufficiently few items miss-
ing to allow prorating for a usable overall score (ie, no 
participant omitted more than three items). One hundred 
and seventy-nine (93.2%) participants of the clinical and 
432 (95.6%) of the nonclinical samples returned completed 
data. The overall omission rate was 0.17%. The items that 
were most often incomplete were items 3 (0.7%) and 25 
(0.7%) in the nonclinical and items 21 (1%) and 32 (1%) in 
the clinical sample.
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Internal consistency
To evaluate the internal reliability, we calculated Cronbach’s 
],44 for all domains and the entire scale for the clinical and 
nonclinical groups. Furthermore, to test if the differences 
between these coefficients were statistically significant, we 
followed the procedure proposed by Feldt et al.45 All domains 
showed an appropriate internal reliability in both samples. 
The levels were within the acceptable range, although being 
lower for the Risk domain (Table 2 and Figure 1).
In comparison with the UK referential data, the pooled 
clinical and nonclinical ] values for all items and all nonrisk 
items showed tight 95% CIs covering the UK referential 
values, and when the clinical and nonclinical samples were 
pooled, the lower confidence limit (CL) was above that for 
the UK data. For Subjective well-being, the Spanish ] was 
above the UK one; for Problems/Symptoms, the clinical 
sample ] had a CI covering the UK one, and the nonclini-
cal ] was slightly lower than the UK nonclinical value with 
the upper CL below the UK value; for Functioning, the CIs 
included the UK referential values. The values for the Risk 
domain were lower than the UK ones (which were the same 
for clinical and nonclinical samples at 0.79), though the CI 
for the combined clinical sample included 0.79.
Testretest stability
Test–retest correlations were strong within domains in the 
nonclinical data (Table 3). The stabilities for all domains 
were satisfactory (range: 0.76–0.87), except for the Risk 
domain (0.45) reflecting the high rate of zero responses in 
answering these items in the nonclinical group. Changes 
of mean values between first and second survey were not 
significant for all scores.
Convergent validity
Correlations between domain scores and the BDI-II and 
the SCL-90-R were calculated (Table 4). Across domain 
scores, correlations were highest against conceptually close 
measures showing an acceptable convergent validity. The 
pattern and the correlations were generally very similar to 
the UK findings,36 although the Spanish correlations between 
the Risk scores and the BDI-II and SCL-90R were lower 
than the UK ones.
Table 2&RHIÀFLHQW] (95% CI) denoting internal consistency for nonclinical and clinical samples
Domains Nonclinical samples Clinical samples Pooled nonclinical  
samples (n452)
Pooled clinical  
samples (n192)Students  
(n325)
Community  
(n127)
Primary care  
(n44)
Secondary  
care (n148)
Subjective well-being 0.80 (0.76, 0.83) 0.80 (0.74, 0.85) 0.79 (0.67, 0.88) 0.81 (0.75, 0.85) 0.80 (0.77, 0.83) 0.81 (0.76, 0.85)
Problems/Symptoms 0.88 (0.86, 0.90) 0.85 (0.81, 0.89) 0.86 (0.80, 0.91)a 0.90 (0.88, 0.92)a 0.88 (0.86, 0.90) 0.90 (0.87, 0.91)
Functioning 0.86 (0.84, 0.88) 0.84 (0.80, 0.88) 0.82 (0.73, 0.89) 0.86 (0.83, 0.89) 0.86 (0.84, 0.88) 0.85 (0.82, 0.88)
Risk 0.73 (0.68, 0.77)b 0.60 (0.48, 0.70)b 0.80 (0.68, 0.87) 0.76 (0.70, 0.82) 0.71 (0.66, 0.75)c 0.77 (0.71, 0.82)c
Nonrisk items 0.94 (0.93, 0.95) 0.93 (0.91, 0.95) 0.92 (0.88, 0.95) 0.85 (0.93, 0.96) 0.94 (0.93, 0.95) 0.94 (0.93, 0.95)
All items 0.94 (0.93, 0.95)b 0.92 (0.90, 0.94)b 0.93 (0.90, 0.95) 0.95 (0.93, 0.96) 0.94 (0.93, 0.95) 0.94 (0.93, 0.95)
Notes: aPVLJQLÀFDQWO\KLJKHU] in the secondary care sample in comparison with primary care sample). bPVLJQLÀFDQWO\KLJKHU] in the students sample in 
comparison with the community sample). cPVLJQLÀFDQWO\KLJKHU] in the clinical sample in comparison with the nonclinical sample).
Abbreviation:&,FRQÀGHQFHLQWHUYDO
Figure 1 Forest plot showing comparison between Spanish scores and UK referential data.
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Differences between clinical and 
nonclinical samples
There were significant differences between clinical and non-
clinical samples in all domains (Table 5) with higher scores 
for the clinical sample than the nonclinical one. With the 
exception of the Problem/Symptoms domain, the effect sizes 
of the differences were similar to the results of the UK study 
with CIs including the UK referential values.36 At 1.4 (CI 
1.22–1.59), the effect size for the Problem/Symptoms score 
is lower than the UK referential that was 1.7 but remains 
respectable as discriminant validity against the clinical/
nonclinical distinction. As in the UK data, the effect size of 
the difference for the Risk score at 0.8 was smaller than for 
all the other scores, actually higher than that in the UK data 
(0.7) but with the CI including the UK value.
The box plot in Figure 2 shows no patients in the clinical 
sample scoring zero and a very few patients (outliers) in the 
nonclinical sample scoring very highly. The box for the one 
sample and the median line bisecting the box for the other 
sample do not overlap.
Sex and age differences
In the nonclinical sample, age was significantly and negatively 
related with all domain scores except Risk: Subjective well-
being (l0.25, P0.001), Problems/Symptoms (P0.23, 
P0.001), and Functioning (l0.18, P0.001); neverthe-
less, those relationships were weak. In the clinical sample 
only, the Functioning domain showed a significant correlation 
with age (l0.19, P0.006), and again, this relationship was 
weak. Regarding sex, only the Subjective well-being domain 
showed a statistical difference between men and women in 
both samples with a small effect size (Table 6).
Correlations between domain scores
Table 7 shows, as expected, significant and generally strong 
correlations between all domains. However, correlations 
between Risk domain scores and the other scores were lower, 
especially in the nonclinical sample.
&OLQLFDOO\VLJQLÀFDQWFKDQJH
Values for clinical significant change were calculated for all 
domains following the c criterion which takes into account 
data from both clinical and nonclinical samples.46 Cutoff 
scores (Table 8) separate typical clinical and nonclinical 
populations and will help to identify the extent to which 
change after treatment is clinically meaningful.
Discussion
To the extent that these psychometric analyses of these 
data from the Spanish version of the CORE-OM are 
good or acceptable, the translation is supported for use in 
Spanish-speaking populations.
Regarding acceptability, considered as the number of 
missing items and unusable measures, the results were 
excellent compared to those obtained in the original English-
language test.37 In our study, the percentage of complete item 
responses was higher for both the clinical and the nonclinical 
sample than in the initial UK testing, which could be taken 
as an evidence not only for the proper design of the question-
naire but also for the quality of the translation process carried 
out to adapt this instrument into Spanish.33
These results are consistent with other studies of vali-
dation such as the Italian, where the percentages of item 
response (96% for the clinical sample and 81% for nonclini-
cal sample)23 are comparable or lower than those observed in 
the current study (93.2% for the clinical and 95.6% for the 
nonclinical sample). Similarly, the results from Sweden have 
Table 3 Testretest stability and changes of mean values between 
ÀUVWDQGVHFRQGVXUYH\LQDQRQFOLQLFDOVDPSOHQ78)
Domains Testretest  
stabilitya
Change
Mean 95% CI P-valueb
Subjective well-being 0.76 0.013 0.13, 0.10 0.80
Problems/Symptoms 0.85 0.045 0.03, 0.12 0.47
Functioning 0.79 0.045 0.02, 0.12 0.16
Risk 0.45 0.008 0.04, 0.04 0.90
Nonrisk items 0.87 0.037 0.02, 0.10 0.36
All items 0.87 0.030 0.02, 0.08 0.43
Notes: aRho Spearman correlation. bWilcoxon test.
Abbreviation:&,FRQÀGHQFHLQWHUYDO
Table 4 Correlations with referential measures in clinical 
samples
Samples n Domains
W P F R R All
Primary care (present study)
BDI-II 39 0.76 0.75 0.65 0.32 0.78 0.74
SCL-90-R 30 0.66 0.56 0.58 0.10 0.64 0.61
Secondary care (present study)
BDI-II 123 0.80 0.82 0.77 0.55 0.85 0.85
SCL-90-R 125 0.70 0.81 0.75 0.51 0.82 0.82
Pooled clinical samples (present study)
BDI-II 162 0.79 0.80 0.74 0.48 0.83 0.83
SCL-90-R 155 0.70 0.77 0.72 0.46 0.79 0.79
Clinical sample (Evans et al36)
BDI-II 29 0.79 0.74 0.78 0.32 0.83 0.81
SCL-90-R 34 0.68 0.87 0.79 0.83 0.85 0.88
Abbreviations: W, subjective well-being; P, problems/symptoms; F, functioning; 
R, risk; BDI-II, Beck Depression Inventory-II; SCL-90-R, Symptom Checklist-90-
Revised.
Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1463
The Spanish version of the CORE-OM
an omission rate of 0.44% of items,25 compared with 0.17% 
in our study. There are no patterns regarding specific items 
in which omissions occurred, indicating that there appears 
to be no connection to any specific dimension.
Considering reliability, the results are acceptable and 
consistent with the analysis made in other studies of adapta-
tion and validation,25–27 as well as with the original UK data. 
In all of these translations, including the present study, some 
differences in the internal consistency between clinical and 
nonclinical samples were identified; however, in all domains, 
the ] value was between 0.7 and 0.9, which means that 
the reliability of the CORE-OM in Spanish has resulted as 
satisfactory as in other versions. ] was lowest for the Risk 
domain, at 0.71 for the pooled nonclinical sample, lower 
than the observed value of 0.79 in the UK validation study 
(CI 0.77–0.81). It seems likely that this difference arises 
because the Risk items are tuned to catch mostly only quite 
significant levels of Risk, giving floor effects that curtail 
variance in nonclinical samples. It seems possible that both, 
the larger size of the UK nonclinical sample compared to 
that reported here and perhaps a higher rate of Risk to self 
in the UK populations, where, particularly in young adults, 
self-harm may be more prevalent than in some other coun-
tries probably including Spain,47,48 may have led to more 
inter-item covariance appearing in this score due to floor 
effects rather than necessarily to much lower population 
covariances.
Test–retest stability in our study was good with the 
exception of the Risk domain score, which again is likely 
to be explained by its small length, floor effects, and the 
intrinsically impulsive (and thus unstable) nature of some 
of the phenomena addressed by these items. Stability cor-
relations were strong but slightly lower than in the UK 
study,36 which is consistent with other results such as the 
Icelandic data.27
Regarding convergent validity, correlations between the 
domain scores of the CORE-OM and the BDI-II and SCL-90-R 
were strong except again for the Risk scores, which is consistent 
with the original UK data.36 In different studies, the CORE-OM 
has shown satisfactory convergent validity with other conceptu-
ally close measures which supports its value as a wider general 
measure for psychotherapy outcome assessment.23,25,27,49
Comparative analysis showed significant differences 
between clinical and nonclinical population in all domains, 
as in other validation studies, demonstrating discriminant 
validity across different countries and languages. The effect 
size (Cohen’s d) values were large for all domains.
As in the original UK data, small but statistically signifi-
cant correlations between scores and age were found in our 
study, more so in the nonclinical than the clinical samples. 
These seem likely to be genuine demographic associa-
tions, but the small effect size illustrates that age does not 
strongly and systematically contaminate scores. However, 
Table 5 Mean and standard deviations for clinical and nonclinical samples
Domains Present study Evans et al*
Nonclinical 
(n452)
Clinical 
(n192)
95% CI Nonclinical 
(n1,084)
Clinical 
(n863)
95% CI
Mean SD Mean SD Difference da Mean SD Mean SD Difference da,b
Subjective well-being 1.18 0.76 2.41 0.95 1.08, 1.36 1.5 (1.31, 1.68) 0.91 0.83 2.37 0.96 1.38, 1.53 1.6 (1.54, 1.74)
Problems/Symptoms 0.99 0.62 1.98 0.87 0.86, 1.10 1.4 (1.22, 1.59) 0.90 0.72 2.31 0.88 1.33, 1.48 1.7 (1.67, 1.88)
Functioning 0.74 0.52 1.56 0.75 0.71, 0.92 1.3 (1.19, 1.55) 0.85 0.65 1.86 0.84 0.95, 1.09 1.3 (1.26, 1.46)
Risk 0.11 0.27 0.48 0.66 0.29, 0.44 0.8 (0.69, 1.04) 0.20 0.45 0.63 0.75 0.38, 0.49 0.7 (0.62, 0.81)
Nonrisk items 0.91 0.55 1.86 0.78 0.84, 1.05 1.5 (1.32, 1.70) 0.88 0.66 2.12 0.81 1.18, 1.31 1.7 (1.59, 1.80)
All items 0.77 0.48 1.62 0.71 0.75, 0.94 1.5 (1.33, 1.71) 0.76 0.59 1.86 0.75 1.04, 1.16 1.6 (1.55, 1.76)
Notes: aCohen effect size parameter. bCohens d has been calculated with the data provided at UK study.36 *Reproduced with permission from Evans C, Connell J, Barkham 
M, et al. Towards a standardised brief out come measure: psychometric properties and utility of the CORE-OM. Br J Psychiatry. 2002;180:5160.36 Available from: http://bjp.
rcpsych.org/content/180/1/51.long.
Abbreviations:&,FRQÀGHQFHLQWHUYDO6'VWDQGDUGGHYLDWLRQ
Figure 2 Box plot of mean item score for all items for clinical and nonclinical 
samples.
Abbreviation: CORE-OM, Clinical Outcomes in Routine Evaluation - Outcome 
Measure.
502
407
402
307
302
207
202
3;4
Enkpkecn
674
Pqpenkpkecn
Ucorng
Qx
gtc
nn"E
QT
G/Q
O"
ue
qtg
Neuropsychiatric Disease and Treatment 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1464
Trujillo et al
the majority of participants in the nonclinical sample were 
students (72%) with a very different age mean and range 
from clinical population. Thus, larger replication studies 
with more diverse nonclinical samples are needed to ascer-
tain the generalizability of these differences. Furthermore, 
a community sample of persons who exceed pensionable 
age, almost absent in these samples, would indicate whether 
specific norms are needed for older populations.17
In the analysis of sex differences in mean scores, only 
Subjective well-being domain showed a statistical difference 
between men and women in both samples, with a small effect 
size in the same direction as the results analyzed in the UK 
version.15 According to the UK authors, sex should be con-
sidered in the interpretation of individual data regardless of 
clinical or nonclinical condition. In the Swedish and Italian 
studies, sex differences were very similar to those found in 
the UK study.23,25,36 However, it seems highly plausible that 
there will be sex effects, which may be culture specific.
Table 8 Male and female cutoff scores between clinical and 
nonclinical populations
Domains Present study Evans et al*
Male Female Male Female
Subjective well-being 1.46 1.82 1.37 1.77
Problems/Symptoms 1.33 1.43 1.44 1.62
Functioning 1.06 1.07 1.29 1.30
Risk 0.24 0.21 0.43 0.30
Nonrisk items 1.24 1.33 1.36 1.50
All items 1.06 1.13 1.19 1.29
Note: *Reproduced with permission from Evans C, Connell J, Barkham M, et al. 
Towards a standardised brief out come measure: psychometric properties and 
utility of the CORE-OM. Br J Psychiatry. 2002;180:5160.36 Available from: http://bjp.
rcpsych.org/content/180/1/51.long.
Table 6 Sex differences in scores for clinical and nonclinical samples
Domains Nonclinical Clinical
Male  
(n94)
Female  
(n343)
95% CI Male  
(n61)
Female  
(n130)
95% CI
Mean SD Mean SD Difference da Mean SD Mean SD Difference da
W 0.95 0.77 1.23 0.76 0.46, 0.11 0.37 (0.60, 0.14) 2.15 1.03 2.51 0.88 0.65, 0.08 0.39 (0.69, 0.08)
P 0.96 0.68 0.99 0.60 0.18, 0.10 0.05 (0.28, 0.18) 1.83 0.92 2.05 0.85 0.48, 0.04 0.25 (0.56, 0.05)
F 0.70 0.57 0.74 0.50 0.15, 0.08 0.08 (0.31, 0.15) 1.57 0.80 1.55 0.73 0.21, 0.25 0.03 (0.28, 0.33)
R 0.13 0.28 0.10 0.27 0.03, 0.08 0.11 (0.12, 0.34) 0.53 0.78 0.44 0.59 0.11, 0.29 0.14 (0.17, 0.44)
All  R 0.85 0.60 0.92 0.54 0.19, 0.05 0.13 (0.35, 0.10) 1.77 0.83 1.90 0.75 0.37, 0.10 0.17 (0.47, 0.14)
All 0.72 0.52 0.77 0.47 0.16, 0.05 0.10 (0.33, 0.12) 1.56 0.78 1.64 0.68 0.30, 0.13 0.11 (0.42, 0.19)
Note: aCohen effect size parameter.
Abbreviations:&,FRQÀGHQFHLQWHUYDO6'VWDQGDUGGHYLDWLRQ:6XEMHFWLYHZHOOEHLQJ33UREOHPV6\PSWRPV))XQFWLRQLQJ55LVN
Table 7 Correlations between Spearmans l values for clinical 
and nonclinical samples
Domains W P F R All  R
Nonclinical (n452)
W
P 0.79
F 0.77 0.75
R 0.33 0.39 0.40
All  R 0.89 0.94 0.91 0.41
All 0.88 0.94 0.91 0.45 0.99
Clinical (n192)
W
P 0.85
F 0.71 0.76
R 0.51 0.56 0.57
All  R 0.89 0.95 0.90 0.60
All 0.88 0.94 0.90 0.67 0.99
Abbreviations: W, subjective well-being; P, problems/symptoms; F, functioning; 
R, Risk.
The strong and positive correlations between the domain 
scores are expected because the items of the CORE-OM are 
designed to evaluate related aspects of psychological distress, 
and the correlations found in this study are not dissimilar 
from those in all explorations to date with the only scale 
showing low correlations with respect to the others being 
Risk.5,23,25–27 This corroborates the special characteristics 
of the Risk domain,38 defined as an oblique factorial scale 
with fairly low positive correlation with the other items and 
domains illustrating that Risk issues are, generally, rather 
distinct from other aspects of psychological distress domains. 
The items were designed as much to provide flags of Risk 
more than to form a robust scale, while ensuring that the 
crucial issue of Risk would contribute to the overall score, 
in contrast to many measures which omit it. The findings in 
this study, in the UK, and of all other translations studied so 
far fit that design.
The cutoff scores obtained in our study are a little 
lower than those reported by the British and Lithuanian 
adaptations.26,36 Our values seem more similar to those found 
in the Italian version,23 with the exception of the Functioning 
domain, which again is lower in our data than the others. 
It seems entirely plausible that cutoff scores, which reflect 
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service provision (implicit in the separation of clinical 
and nonclinical populations), will show cultural/national 
variations. Currently, data about cutoff scores for reliable 
change are being collected, and we hope that the results will 
be published soon.
Overall, the results provide very reassuring information 
about the psychometric properties and the potential of the 
Spanish version of the CORE-OM. The limitations of the 
study are the nonrandom sample frames, the relatively limited 
sample sizes, lack of interview measures, and relatively limited 
number of convergent validity tests. However, these results 
clearly support the use of the measure and justify develop-
ment of subsequent studies with the forms derived from this 
questionnaire. A Catalan translation has been completed, 
and psychometric exploration of it is currently in progress. 
Another translation into Spanish considered more suited for 
use in Argentina has been completed but not tested. Initial 
discussions with a few natives suggest that the Spanish ver-
sion assessed in this article is considered acceptable for use 
in Chile, Mexico, and Colombia. Further exploration of its 
acceptability, and then its psychometric properties in other 
Spanish-speaking countries other than Spain, is encouraged.
In summary, this study presents the Spanish version of the 
CORE-OM showing that it is a reliable and valid instrument 
for assessing psychological distress in patients and providing 
feedback to their therapists about overall change and ongoing 
progress. An additional advantage of this instrument in all 
its versions, including Spanish, is that it can be used without 
payment of license fees, and this should facilitate generation 
of much more evidence about the efficacy and effectiveness 
of psychological therapies in Spain and at least some other 
Spanish-speaking populations.
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